PubRank

Use of appropriate initial treatment among adolescents and young adults with cancer.

PubWeight™: 0.83‹?›

🔗 View Article (PMC 4200030)

Published in J Natl Cancer Inst on October 09, 2014

Authors

Arnold L Potosky1, Linda C Harlan2, Karen Albritton2, Rosemary D Cress2, Debra L Friedman2, Ann S Hamilton2, Ikuko Kato2, Theresa H M Keegan2, Gretchen Keel2, Stephen M Schwartz2, Nita L Seibel2, Margarett Shnorhavorian2, Michele M West2, Xiao-Cheng Wu2, AYA HOPE Study Collaborative Group

Author Affiliations

1: Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC (ALP); Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD (LCH); Cook Children's Medical Center and University of North Texas Health Science Center Fort Worth, TX (KA); Public Health Institute/Cancer Registry of Greater California, Sacramento, CA (RDC); Monroe Carell Jr. Children's Hospital, Vanderbilt-Ingram Cancer Center, Nashville, TN (DLF); Keck School of Medicine, University of Southern California, Los Angeles, CA (ASH); Departments of Oncology and Pathology, Wayne State University, Detroit, MI (IK); Cancer Prevention Institute of California, Fremont, CA (THMK); School of Medicine, Stanford University, Stanford, CA (THMK); Information Management Services, Inc., Silver Spring, MD (GK); Epidemiology Program, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA (SMS); Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD (NLS); Department of Urology, Division of Pediatric Urology, University of Washington, Seattle Children's Hospital, Seattle, WA (MS); Department of Epidemiology, University of Iowa, Iowa City, IA (MMW); Louisiana State University, New Orleans, LA (XCW). alp49@georgetown.edu.
2: Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC (ALP); Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD (LCH); Cook Children's Medical Center and University of North Texas Health Science Center Fort Worth, TX (KA); Public Health Institute/Cancer Registry of Greater California, Sacramento, CA (RDC); Monroe Carell Jr. Children's Hospital, Vanderbilt-Ingram Cancer Center, Nashville, TN (DLF); Keck School of Medicine, University of Southern California, Los Angeles, CA (ASH); Departments of Oncology and Pathology, Wayne State University, Detroit, MI (IK); Cancer Prevention Institute of California, Fremont, CA (THMK); School of Medicine, Stanford University, Stanford, CA (THMK); Information Management Services, Inc., Silver Spring, MD (GK); Epidemiology Program, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA (SMS); Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD (NLS); Department of Urology, Division of Pediatric Urology, University of Washington, Seattle Children's Hospital, Seattle, WA (MS); Department of Epidemiology, University of Iowa, Iowa City, IA (MMW); Louisiana State University, New Orleans, LA (XCW).

Articles citing this ↘

Use of patient registries and administrative datasets for the study of pediatric cancer. Pediatr Blood Cancer (2015) 2.02

Risk-Benefit Analysis of Pediatric-Inspired Versus Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Protocols for Acute Lymphoblastic Leukemia in Adolescents and Young Adults. J Adolesc Young Adult Oncol (2016) 0.75

Facilitating Teamwork in Adolescent and Young Adult Oncology. J Oncol Pract (2016) 0.75

Articles cited by this ↗

Consensus methods for medical and health services research. BMJ (1995) 17.94

Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol (2009) 4.20

Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood (2007) 3.79

Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood (2003) 3.18

What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood (2008) 3.03

Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95. J Clin Oncol (2013) 2.98

Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med (2010) 2.97

The distinctive biology of cancer in adolescents and young adults. Nat Rev Cancer (2008) 2.91

Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer (2004) 2.78

Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer (2006) 2.77

Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood (2010) 2.58

Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin's lymphoma--a report from the Children's Oncology Group. J Clin Oncol (2012) 2.49

A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood (1995) 2.43

Adolescents and young adults with cancer: the scope of the problem and criticality of clinical trials. Cancer (2006) 2.38

Recruitment and follow-up of adolescent and young adult cancer survivors: the AYA HOPE Study. J Cancer Surviv (2011) 2.15

Young adult oncology: the patients and their survival challenges. CA Cancer J Clin (2007) 2.11

Access to pediatric cancer care by age, race, and diagnosis, and outcomes of cancer treatment in pediatric and adolescent patients in the state of Georgia. J Clin Oncol (2007) 2.00

Association between insurance and socioeconomic status and risk of advanced stage Hodgkin lymphoma in adolescents and young adults. Cancer (2012) 1.99

Subsequent malignancies in children treated for Hodgkin's disease: associations with gender and radiation dose. Int J Radiat Oncol Biol Phys (2008) 1.95

Cancer in 15- to 29-year-olds by primary site. Oncologist (2006) 1.92

Adolescent and young adult oncology: an emerging field. J Clin Oncol (2010) 1.75

A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood (2009) 1.74

BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group. Blood (2010) 1.68

Challenges in the recruitment of adolescents and young adults to cancer clinical trials. Cancer (2007) 1.54

Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol (2010) 1.46

The management of cancer in the older adolescent. Eur J Cancer (2003) 1.45

Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys (2013) 1.40

Analysis of prognostic factors in Ewing sarcoma using a population-based cancer registry. Cancer (2010) 1.33

Participation of adolescents with cancer in clinical trials. Cancer Treat Rev (2007) 1.04

Socioeconomic Impacts on Survival Differ by Race/Ethnicity among Adolescents and Young Adults with Non-Hodgkin's Lymphoma. J Cancer Epidemiol (2010) 1.01

Disparities in survival after Hodgkin lymphoma: a population-based study. Cancer Causes Control (2009) 1.00

Lymphoma in adolescents and young adults. Semin Oncol (2009) 0.97

Adolescent and young adult (AYA) oncology: the first A. Pediatr Hematol Oncol (2007) 0.95

Pediatric Hodgkin lymphoma: trade-offs between short- and long-term mortality risks. Blood (2012) 0.93

Socioeconomic inequality and short-term outcome in Hodgkin's lymphoma. Int J Cancer (2007) 0.91

Proceedings of a workshop: bridging the gap in care and addressing participation in clinical trials. Cancer (2006) 0.87

Late effects of treatment for Hodgkin lymphoma. J Natl Compr Canc Netw (2006) 0.86

How NCCN guidelines can help young adults and older adolescents with cancer and the professionals who care for them. J Natl Compr Canc Netw (2012) 0.83

Hodgkin lymphoma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol (2012) 0.83

Evolution of radiation therapy within the German Hodgkin Study Group trials. J Natl Compr Canc Netw (2011) 0.79

Ethnicity and age disparities in Ewing sarcoma outcome. Fetal Pediatr Pathol (2012) 0.78

Who should be treating adolescents and young adults with acute lymphoblastic leukaemia? Eur J Cancer (2003) 0.78

The unique characteristics of ovarian carcinogenesis in the adolescent and young adult population. Semin Oncol (2009) 0.77

Articles by these authors ⇆

Recruitment and follow-up of adolescent and young adult cancer survivors: the AYA HOPE Study. J Cancer Surviv (2011) 2.15

Fertility preservation knowledge, counseling, and actions among adolescent and young adult patients with cancer: A population-based study. Cancer (2015) 1.55

Unmet adolescent and young adult cancer survivors information and service needs: a population-based cancer registry study. J Cancer Surviv (2012) 1.49

Unmet Support Service Needs and Health-Related Quality of Life among Adolescents and Young Adults with Cancer: The AYA HOPE Study. Front Oncol (2013) 1.08

Medical care in adolescents and young adult cancer survivors: what are the biggest access-related barriers? J Cancer Surviv (2014) 0.98

"Cancer sucks," and other ponderings by adolescent and young adult cancer survivors. J Psychosoc Oncol (2014) 0.87

Cancer-related information needs and cancer's impact on control over life influence health-related quality of life among adolescents and young adults with cancer. Psychooncology (2015) 0.79

Impact of the AYA HOPE Comorbidity Index on Assessing Health Care Service Needs and Health Status among Adolescents and Young Adults with Cancer. Cancer Epidemiol Biomarkers Prev (2015) 0.75

Knowledge of Clinical Trial Availability and Reasons for Nonparticipation Among Adolescent and Young Adult Cancer Patients: A Population-based Study. Am J Clin Oncol (2016) 0.75